Book a demo
Topics · AI-DLC

Healthcare Payors AI-DLC Build vs. Buy | Moring

Build versus buy for a payor AI-DLC is really a question of what to own: buy standardized capability where products fit, build where proprietary workflows and clinical criteria differentiate, and always build the governance layer yourself, because it must encode your own policies and produce evidence in your own lifecycle structure regardless of which agents you run.

On this page
  1. Short answer
  2. How it works
  3. FAQs
  4. Related reading
  5. Sources

Short answer

Build versus buy for a payor AI-DLC is really a question of what to own: buy standardized capability where products fit, build where proprietary workflows and clinical criteria differentiate, and always build the governance layer yourself, because it must encode your own policies and produce evidence in your own lifecycle structure regardless of which agents you run.

How it works

Healthcare organizations evaluating AI usually reach the same question: should we build, buy, or combine the two. The honest answer is that the question is broader than technology. A packaged platform may get a payor moving quickly but may not fit its workflows, data environment, or compliance requirements. A custom solution gives control but leaves the organization responsible for architecture, integration, validation, monitoring, and long-term operation. The useful formulation is not build or buy; it is what should we own, what can we standardize, and where does customization actually create value. For payor delivery, that turns procurement into an architecture and governance decision.

The standard guidance maps cleanly onto payor reality. Buy when the problem is reasonably standardized and an existing product meets requirements for integration, security, compliance, and operation. Build when the capability depends on proprietary workflows, specialized data, unique integrations, or intellectual property that must stay controlled. Use a hybrid where established technology can carry the commodity layers while the differentiating logic stays in-house. A payor’s claims editing logic, medical policy interpretation, and prior authorization criteria are exactly the proprietary layer that argues for building; document processing and infrastructure plumbing argue for buying.

The AI-DLC adds a decisive wrinkle: whatever you buy, the governance layer must be yours. A coding or workflow agent without a governance layer becomes a powerful but uncontrolled actor, generating changes that may violate data handling rules, and leaving regulators no evidence of oversight. The governance layer converts organizational policy into technical constraint. That layer cannot be purchased as a generic product because its entire function is to encode your policies, architecture standards, and review requirements, and to produce audit-ready evidence in your lifecycle’s structure.

Field experience shows this layer can be assembled quickly when the inputs already exist. A governance harness for agent-driven development was built in days working alongside one of the largest insurers, and it was deliberately agent-agnostic: it works with whichever coding agents the teams choose, because it is built from knowledge the institution already holds rather than from the agent vendor’s assumptions. For a payor, that is the pattern to replicate. Own the harness and the lifecycle; treat the agents as replaceable execution inside it. This also preserves negotiating leverage with vendors, since any agent can be swapped without rebuilding governance.

Unstructured adoption is the alternative, and its costs are documented. Bolting agents onto workflows that were not redesigned for them produces fragmentation, technical debt, and operational risk, and the dominant failure mode reported by engineering leaders is exactly that: adopting tools without changing the operating model, then waiting for delivery gains that do not arrive. Buying a platform does not escape this, because the platform inherits the payor’s obligation structure the moment it touches member data or payment decisions. A bought platform still needs an owned lifecycle around it.

The decision framework therefore separates cleanly. Buy the standardized execution surfaces: infrastructure, document handling, and mature platform capabilities. Build the differentiating logic: the medical policy content, workflow criteria, and integration with the systems of record that define how the plan actually operates. Build the governance layer unconditionally, since it is the piece that makes either choice defensible. Evaluate the result by traceability and approval coverage across the lifecycle stages, then measure delivery outcomes; assistant usage alone has never told anyone whether releases became safer or faster.

Frequently asked questions

Which parts of a payor AI-DLC make sense to buy rather than build?

Buy where the problem is standardized: infrastructure, document processing, and mature platform capabilities that already meet integration, security, and operational requirements. Build where the payor differentiates: proprietary medical policy interpretation, prior authorization criteria, claims editing logic, and integrations with systems of record. The split follows a simple test of what to own versus what to standardize, applied to the delivery lifecycle rather than to technology in the abstract.

Why must the governance layer of an AI-DLC always be built in-house?

Because its function is to convert the payor’s own policies into technical constraints and to produce audit-ready evidence in the lifecycle’s structure. A generic purchased layer cannot encode medical policy boundaries, review requirements, and data handling rules specific to the plan. Demonstrated implementations built the harness in days precisely because it draws on knowledge the organization already holds, and keeping it agent-agnostic means agents can be swapped without dismantling governance.

What happens when a payor buys an AI platform but skips the governed lifecycle?

The platform inherits the obligation structure the moment it touches member data or payment decisions, but nothing generates the evidence that oversight occurred. This is the documented failure mode: agents bolted onto unchanged workflows produce fragmentation, technical debt, and operational risk instead of delivery gains. Procurement success and governance failure can coexist, which is why the lifecycle decision matters more than the vendor decision.

How should a payor evaluate its build-versus-buy decision after deployment?

Evaluate by traceability and approval coverage across the lifecycle stages, then measure delivery outcomes. Assistant usage statistics never indicated whether releases became safer or faster. For a healthcare payor, the operative questions are whether every agent-driven change can be reconstructed from records and whether human approval gates operated where member or financial consequence was involved, regardless of which vendor supplied the execution layer.

Sources

  1. moring.ai
  2. aws.amazon.com
  3. ranthebuilder.cloud
  4. linkedin.com
  5. firstlinesoftware.com
  6. himssconference.com
  7. - artificialintelligenceact.eu